BEIJING, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that the Company entered into a strategic cooperation agreement (the “Agreement”) with Beijing Xihuan Psychological Consulting Co., Ltd. (“XHPC”), a Beijing-based comprehensive psychological consulting company, on February 21, 2022 to jointly build an industry-university-research-medical collaborative platform (the “Platform”) for psychological rehabilitation of tumor patients. Shineco and XHPC plan to use the Platform to conduct research on critical topics, introduce the results of relevant research into the Company's tumor clinical treatment system, and improve the development of Shineco's digital tumor diagnosis and treatment.
XHPC is a professional integrated psychological consulting company, providing one-stop social psychological solutions for enterprises, institutions, and certain social groups, such as psychological care organizations for youth. Over the years, XHPC has built a system to tackle the challenges of psychological and behavioral problems through psychological counseling, corporate employee assistance program (EAP) services, and psychological evaluation, which effectively promotes the healthy development of enterprises and improves the mental health of their employees.
The modern treatment of tumors has evolved into a multi-disciplinary and comprehensive treatment to involve multiple factors, such as mental, physical, and societal. The cooperation between the two parties will focus on the mental health of tumor patients. Leveraging both parties’ respective advantages, the two parties expect to build an industry-university-research-medical platform and introduce the results of relevant research into Shineco’s tumor clinical treatment system by conducting research on the mental health and intervention of tumors. By establishing an early intervention collaboration mechanism, the parties aim to create a regional integrated and collaborative diagnosis and treatment model to help improve the rate of early diagnosis and early treatment of tumor diseases.
Ms. Xueyuan Shi, CEO of XHPC, commented, “We are very pleased to enter into the Agreement with Shineco to build an integrated industry-university-research-medical platform to jointly carry out mental health guidance and intervention for tumors patients. We have accumulated solid practical experience in psychological counseling, corporate EAP services, and psychological evaluation. With the help of a professional team of psychological consultants, we strive to provide personalized mental health treatment plans for patients to keep them with a positive attitude. Moving forward, we will work closely with Shineco, leveraging the resources of each other to help tumor patients overcome mental challenges in the treatment process and aim to improve the quality of their lives."
Ms. Jennifer Zhan, CEO of Shineco, commented, “We are very pleased to witness this cooperation with XHPC, which is another new milestone in the development of Shineco’s digital tumor diagnosis and treatment. We expect to take the mental health guidance and intervention of tumor patients as the direction, build an industry-university-research-medical collaborative platform, actively conduct research and development, and promote the results of scientific research. In order to enhance the prevention and treatment of mental diseases and improve the mental health of patients, through the integration and promotion of physical, psychological, and social aspects, Shineco together with its partner plan to further strengthen the intervention on the mental health of tumor patients and provide patients with closed-loop services for tumor diagnosis and treatment to benefit more patients.”
About Shineco, Inc.
Incorporated in Delaware in August 1997 and headquartered in Beijing, China, Shineco is a holding company. Utilizing modern engineering technologies and biotechnologies, Shineco produces, among other products, Chinese herbal medicines, organic agricultural produce, and specialized textiles. For more information about Shineco, please visit www.biosisi.com.
This press release contains information about Shineco's view of its future expectations, plans and prospects that constitute forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, the impact of the COVID-19 pandemic, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. Shineco encourages you to review other factors that may affect its future results in its registration statement and in its other filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based on current expectations and Shineco assumes no obligation to update these forward-looking statements except as required by the applicable rules and regulations.
For more information, please contact:
Ascent Investor Relations LLC
Source: Shineco, Inc.